Merck & Co., Inc. - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Merck & Co., Inc. operates through two primary segments: Pharmaceutical (human health pharmaceuticals and vaccines) and Animal Health. The company is a large accelerated filer incorporated in New Jersey. As of April 30, 2025, there were approximately 2.51 billion shares of common stock outstanding.
Key Financial Metrics
| Metric ($ in millions) | Q1 2025 | Q1 2024 |
|---|---|---|
| Sales | $15,529 | $15,775 |
| Net Income (Attributable to Merck) | $5,079 | $4,762 |
| Diluted EPS | $2.01 | $1.87 |
| Operating Cash Flow | $2,500 | $3,090 |
| Free Cash Flow (Approx.) | $1,172 | $2,229 |
| Long-Term Debt | $33,484 | $34,462 |
| Cash & Cash Equivalents | $8,629 | $13,242 |
| Gross Margin | 78.0% | 77.6% |
Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($1,328 million).
Material Changes vs. Prior Period
- Sales: Decreased 2% to $15.5 billion. The decline was driven by lower vaccine sales (primarily Gardasil/Gardasil 9 due to paused shipments to China) and virology (Lagevrio), partially offset by growth in oncology (Keytruda), cardiovascular (Winrevair), and diabetes (Januvia).
- Profitability: Net income increased 7% to $5.1 billion despite lower sales, driven by a lower effective tax rate (13.9% vs. 15.9%) and reduced restructuring costs ($69 million vs. $123 million).
- Research & Development: Expenses decreased 9% to $3.6 billion. This decline is largely attributable to the absence of the $656 million charge recorded in Q1 2024 for the Harpoon Therapeutics acquisition.
- Segment Performance: Pharmaceutical segment sales declined 3% to $13.6 billion. Animal Health segment sales grew 5% to $1.6 billion.
- Geographic Mix: U.S. sales grew 14% to $8.5 billion, while International sales declined 16% to $7.0 billion, heavily impacted by the China vaccine situation.
Guidance, Outlook, and Risks
- Business Development: Merck entered an exclusive license agreement with Hengrui Pharma for HRS-5346 (Lipoprotein(a) inhibitor), expecting a $200 million R&D charge in Q2 2025. The company also acquired a WuXi Vaccines facility in Ireland for $437 million.
- Regulatory & Pricing Risks:
- IRA Impact: Januvia is subject to government price negotiation effective Jan 1, 2026. Janumet and Janumet XR are included for price setting effective Jan 1, 2027.
- Tariffs: Management anticipates approximately $200 million in additional expenses in 2025 due to tariffs, primarily related to imports into China.
- Patent Expirations: Key U.S. exclusivity for Januvia/Janumet is expected to end in May 2026, and Janumet XR in July 2026, following favorable court rulings on salt/polymorph patents.
- Legal Contingencies:
- IRS Examination: Received Notices of Proposed Adjustment (NOPAs) regarding the 2017/2018 transition tax, proposing an increase of ~$1.3 billion plus $260 million in penalties. Merck intends to vigorously contest this.
- Product Liability: Approximately 500 cases pending regarding Dr. Scholl's foot powder and 245 cases regarding Gardasil/Gardasil 9. Merck recently won summary judgment in 16 Gardasil bellwether cases.
- Capital Allocation: The company repurchased $1.2 billion of stock in Q1 2025. A new $10 billion share repurchase authorization was approved in January 2025, leaving $11.2 billion remaining as of March 31, 2025.
Investor Verification Checklist
- China Vaccine Exposure: Verify the duration of the shipment pause to China for Gardasil/Gardasil 9 and the impact on 2025 full-year vaccine revenue guidance.
- IRS Dispute: Monitor the status of the $1.56 billion (tax + penalties) IRS proposed adjustment and the likelihood of a material charge if the appeal fails.
- Keytruda Growth: Assess the sustainability of Keytruda's 4% growth given the negative pricing impact of new EU indications and potential biosimilar competition timelines.
- Januvia Pricing: Confirm the net pricing impact of the Medicaid rebate cap elimination and the upcoming IRA price negotiation in 2026.
- R&D Pipeline: Track the FDA review status of subcutaneous Keytruda (PDUFA date Sept 2025) and patritumab deruxtecan (following a CRL in June 2024).